Therapeutic Potential of Retinoid X Receptor Modulators for the Treatment of the Metabolic Syndrome
Author Information
Author(s): Jane A. Pinaire, Anne Reifel-Miller
Primary Institution: Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN, USA
Hypothesis
Can RXR-selective ligands effectively treat metabolic syndrome by improving glucose metabolism and reducing obesity?
Conclusion
RXR-specific ligands show promise in treating metabolic syndrome by lowering glucose levels and reducing obesity, despite some side effects.
Supporting Evidence
- Rexinoids have been shown to have glucose-lowering and insulin-sensitizing effects in animal models.
- LG101506 selectively maintains desirable effects while minimizing undesirable side effects.
- Continued research may lead to improved RXR-specific ligands for treating obesity and diabetes.
Takeaway
This study looks at special compounds that might help people with obesity and diabetes by making their bodies better at using sugar, but they can also cause some problems.
Methodology
The review examines the effects of various RXR-selective ligands on glucose metabolism and obesity in animal models.
Limitations
The study primarily focuses on animal models, which may not fully represent human responses.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website